<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of microbiology, epidemiology and immunobiology</journal-id><journal-title-group><journal-title xml:lang="en">Journal of microbiology, epidemiology and immunobiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Журнал микробиологии, эпидемиологии и иммунобиологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0372-9311</issn><issn publication-format="electronic">2686-7613</issn><publisher><publisher-name xml:lang="en">Central Research Institute for Epidemiology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">230</article-id><article-id pub-id-type="doi">10.36233/0372-9311-2017-6-49-55</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">EFFECT OF METHODS OF IMMOBILIZATION OF ERYTHROPOIETIN ON THE SENSITIVITY FOR THE DETECTION OF SPECIFIC IgG TO EPO IN EXPERIMENTAL ANIMALS SERA</article-title><trans-title-group xml:lang="ru"><trans-title>ВЛИЯНИЕ МЕТОДОВ ИММОБИЛИЗАЦИИ ЭРИТРОПОЭТИНА НА ЧУВСТВИТЕЛЬНОСТЬ ВЫЯВЛЕНИЯ СПЕЦИФИЧЕСКИХ IgG К EПB В СЫВОРОТКАХ КРОВИ ЭКСПЕРИМЕНТАЛЬНЫЙ ЖИВОТНЫХ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kudryashova</surname><given-names>A. M.</given-names></name><name xml:lang="ru"><surname>Кудряшова</surname><given-names>А. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Borisova</surname><given-names>O. V.</given-names></name><name xml:lang="ru"><surname>Борисова</surname><given-names>О. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mikhailova</surname><given-names>N. A.</given-names></name><name xml:lang="ru"><surname>Михайлова</surname><given-names>Н. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lonshakov</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Лоншаков</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Katlinsky</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Катлинский</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Mechnikov Research Institute of Vaccines and Sera</institution></aff><aff><institution xml:lang="ru">НИИ вакцин и сыворотоким. И.И.Мечникова</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Biopharmaceutical company LLC «Fort»</institution></aff><aff><institution xml:lang="ru">Биофармацевтическая компания ООО «Форт»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-12-28" publication-format="electronic"><day>28</day><month>12</month><year>2017</year></pub-date><volume>94</volume><issue>6</issue><issue-title xml:lang="ru"/><fpage>49</fpage><lpage>55</lpage><history><date date-type="received" iso-8601-date="2019-04-10"><day>10</day><month>04</month><year>2019</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Kudryashova A.M., Borisova O.V., Mikhailova N.A., Lonshakov D.V., Katlinsky A.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, Кудряшова А.М., Борисова О.В., Михайлова Н.А., Лоншаков Д.В., Катлинский А.В.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Kudryashova A.M., Borisova O.V., Mikhailova N.A., Lonshakov D.V., Katlinsky A.V.</copyright-holder><copyright-holder xml:lang="ru">Кудряшова А.М., Борисова О.В., Михайлова Н.А., Лоншаков Д.В., Катлинский А.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://microbiol.crie.ru/jour/article/view/230">https://microbiol.crie.ru/jour/article/view/230</self-uri><abstract xml:lang="en"><p>Aim. The study of the effect of the erythropoietin coating procedure on sensitivity using the same secondary detection methods to quantify anti-EPO IgG positive animal sera. Materials and methods. Sera from experimental animals - rabbits and guinea pigs - after rhEPO injection were used. The methods includes directly coated ELISA and two types of immunochemical immobilization: capturing biotinylated rhEPO on streptavidin coated microtiier plates and capturing rhEPO via a specific antibody Results. Immunochemical rhEPO immobilization results in a sensitivity from 2 to 10 of magnitude higher than direct coating of rhEPO. Conclusion. Our findings show that the method of rhEPO immobilization to microtiter plates is a critical determinant for the sensitivity of ELISA used for measuring anti-EPO antibodies. Assays in which rhEPO was captured via a specific mAb, or in which biotinylated rhEPO was captured via streptavidin, are preferred to detect serum antibodies to native structural state.</p></abstract><trans-abstract xml:lang="ru"><p>Цель. Исследование влияния методов иммобилизации эритропоэтина на чувствительность выявления специфических IgG к человеческому эритропоэтину (чЭПО) в сыворотках крови экспериментальный животных. Материалы и методы. В работе использовали сыворотки крови кроликов и морских свинок, полученных после введения препаратов эритропоэтина. Схемы иммуноферментного метода включали варианты пассивной иммобилизации человеческого рекомбинантного эритропоэтина (чрЭПО) на планшете и два варианта иммунохимической иммобилизации: связывание биотинилированного чрЭПО в лунках планшета с пассивно иммобилизованным стрептавидином и связывание чрЭПО с пассивно иммобилизованными на планшетах антителами к эритропоэтину. Результаты. Показано, что иммунохимическая иммобилизация приводит к повышению чувствительности в диапазоне от 2 до 10 раз при выявлении антител к чЭПО по сравнению с пассивной иммобилизацией. Заключение. Полученные результаты свидетельствуют о значительном влиянии метода иммобилизации чрЭПО на чувствительность выявления антител к чЭПО. При выявлении антител к нативным конформационным эпитопам иммунохимическая иммобилизация является предпочтительной.</p></trans-abstract><kwd-group xml:lang="en"><kwd>serum of animals</kwd><kwd>ELISA</kwd><kwd>antibodies</kwd><kwd>erythropoietin</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>сыворотки животных</kwd><kwd>твердофазный ИФА</kwd><kwd>антитела</kwd><kwd>эритропоэтин</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Barger Т.Е., KuckA.J., Chirmule N. etal. Detection ofanti-ESA antibodies in human samples from PRCA and non-PRCA patients: an immunoassay platform comparison. Nephrol Dial. Transplant. 2012, 27: 688-693.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Barger T.E., Wrona D., Goletz T.J. et al. A detailed examination of the antibody prevalence and characteristics of anti-ESA antibodies.Nephrol. Dial Transplant. 2012, 27 (10): 3892- 3899.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Butler J.E. Solid supports in enzyme-linked immunosorbent assays and other solid phase immunoassays. Methods Mol. Med. 2004, 94: 333-372.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Casadevall N., Nataf J., Viron B. et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. New Engl. J. Med. 2002, 346: 469-475.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Gross J., Moller R., Henke W. et al. Detection of anti-EPO antibodies in human sera by a bridging ELISA is much more sensitive when coating biotinylated rhEPO to streptavidin rather than using direct coating of rhEPO. J. Immunol. Methods. 2006, 313 (1-2): 176-182.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Herrington W., Wieser C., Rosenkranz A.R. Pure red cell aplasia after treatment of renal anaemia with epoetin theta. Clin. Kidney J. 2013, 6 (5): 539-542.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Lonshakov D. V., Sheremet'ev S. V., Belosludtseva E. M. et al. Synthesis of 4-aminobenzoic acid esters of polyethylene glycol and their use for pegylation of therapeutic proteins. RSC Adv. 2015, 5 (53): 42903-42909.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Macdougall I.C., Casadevall N., Locatelli F. et al. Incidence of erythropoietin antibody-me-diated pure red cell aplasia: the prospective immunogenicity surveillance registry (PRIMS). Nephrol Dial Transplant. 2015, 30 (3): 451-460.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Macdougall I.C., Roger S.D., de Francisco A. et al. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis stimulating agents: new insights. Kidney Int. 2012, 81:727-732.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Rabe М., Verdes D., Seeger S. Understanding protein adsorption phenomena at solid surfaces. Advances Colloid Interface Sci. 2011, 162 (1-2): 87-106.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Shin S.K., Ha S.K., Lee K.W. et al. Application of a bridging ELISA for detection of antierythropoietin binding antibodies and a cell-based bioassay for neutralizing antibodies in human sera. J. Pharm. Biomed Anal. 2010, 52: 289-293.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Van Der Zee J.S., Van Swieten P., Aalberse R.C. Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J. Immunol. 1986, 137: 3566-3571.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Weeraratne D.K., Kuck A.J., Chirmule N. et al. Measurement of anti-erythropoiesis stimulating agent IgG4 antibody as an indicator of antibody-mediated pure red cell Aplasia. Clin. Vac. Immunol.2013, 20 (1): 46-51.</mixed-citation></ref></ref-list></back></article>
